Clinical trial
Epidemiology and Treatment of HR+/HER2- Breast Cancer in England
NCT07498413 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Epidemiology and Treatment of HR+/HER2- Breast Cancer in England
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 8, 2023
- Completion date
- July 18, 2025
- Enrollment
- Not reported
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer